Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT), an affiliate of the Cystic Fibrosis Foundation, announced it will extend funding for continued collaboration with Proteostasis Therapeutics, Inc., for the development of new therapies to treat the most common CF mutation, Delta F508.
Site Search
The U.S. Food and Drug Administration announced today it has approved Kalydeco™ to treat people ages 6 and older who have one of eight additional cystic fibrosis mutations.
The U.S. Food and Drug Administration (FDA) announced today that it has approved the use of ivacaftor (Kalydeco™) to treat people with cystic fibrosis ages 6 and older who have the R117H mutation.
The European Commission has approved the cystic fibrosis drug Orkambi® for people with two copies of the F508del mutation ages 12 and older in the European Union.
Today, more than 4,000 cystic fibrosis research scientists, clinicians and caregivers are gathering in Phoenix for the 29th Annual North American Cystic Fibrosis Conference (NACFC) in the largest collaborative forum of its kind.
HealthWell to offer co-pay assistance for CF-specific, FDA-approved drugs including prescribed vitamins and supplements.
To the CF Foundation Staff and CF Community: Today, after 35 years with the Cystic Fibrosis Foundation -- and 21 years as president and CEO -- Robert J. Beall, Ph.D., has announced he is stepping down.
The Cystic Fibrosis Foundation's drug development model, mission and leadership are featured on the front page of The Washington Post today.
Today we received the exciting news that the U.S. Food and Drug Administration has approved Orkambi for people with cystic fibrosis ages 12 and older who have two copies of the F508del gene mutation, the most common CF mutation.